In BLISS-76, 43.2% (118/273) of the high-dose belimumab group compared with 33.8% (93/275) of the placebo group achieved the primary endpoint at week 52. 7 This difference, although modest in ...

Furie et al. now report favorable results for their phase I trial of belimumab—a fully human, neutralizing, monoclonal antibody against B-lymphocyte stimulator—which both stimulates ...

Benlysta (belimumab) is a prescription drug that treats lupus by reducing the number of certain proteins in your blood that attack your body. Your response to this drug may vary based on your ...

Belimumab combined with standard therapy demonstrated significant improvements in mucocutaneous symptoms in patients with systemic lupus erythematosus (SLE) compared with placebo with standard ...

But in the past few years, a number of highly effective drugs have got NHS approval. This includes the injection belimumab, which was approved in 2021.